webinar register page

Webinar banner
Cytisinicline and Smoking Cessation Virtual KOL Roundtable
Overview of ORCA-2 Phase 3 Program and results of RAUORA head-to-head study of Cytisinicline vs. Chantix® (varenicline)

• Michael Higgins, MBA, Ladenburg Thalmann
• Thomas Flaten, Lake Street Capital Markets

Featuring KOLs:
• Nancy Rigotti, MD – Professor of Medicine, Harvard Medical School, Director of Tobacco Research & Treatment, Massachusetts General Hospital, and ORCA-2 Principal Investigator
• Mitchell Nides, PhD – President, LA Clinical Trials LLC, ORCA-1 Principal Investigator
• Neal Benowitz, MD – Professor of Medicine, Emeritus, University of California, San Francisco
• Judith Prochaska, PhD, MPH – Professor of Medicine, Stanford University
• Scott Leischow, PhD – Professor and Director, Clinical and Translational Science, Arizona State University, Former Senior Advisor for Tobacco Policy at HHS

Chantix® is a registered trademark of Pfizer Inc.

Nov 17, 2020 12:00 PM in Eastern Time (US and Canada)

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Jason Wong.